Abstract
Ischemia and reperfusion injury leads to a complex pathophysiological process, which in turn results in the generation of free radicals. Peroxynitrite, a highly reactive species causes DNA single strand breaks, which activates the nuclear enzyme, poly (ADP-ribose) polymerase (PARP). The activation of PARP leads to an energy consuming inefficient repair cycle with subsequent depletion of NAD+ and ATP pools and necrotic cell death. The present review overviews the pathophysiological role of the peroxynitrite-PARP pathway in cardiac ischemia/reperfusion injury with special reference to the therapeutic potential of PARP inhibitors in the treatment of this disease.
Keywords: nitric oxide (no), peroxynitrite, ischemia reperfusion, dna damage, nad, parp inhibitor, reperfused myocardium, inflammatory pathways
Current Vascular Pharmacology
Title: Role of Nitrosative Stress and Poly(ADP-ribose) Polymerase Activation in Myocardial Reperfusion Injury
Volume: 3 Issue: 3
Author(s): Gabor Szabo and Susanne Bahrle
Affiliation:
Keywords: nitric oxide (no), peroxynitrite, ischemia reperfusion, dna damage, nad, parp inhibitor, reperfused myocardium, inflammatory pathways
Abstract: Ischemia and reperfusion injury leads to a complex pathophysiological process, which in turn results in the generation of free radicals. Peroxynitrite, a highly reactive species causes DNA single strand breaks, which activates the nuclear enzyme, poly (ADP-ribose) polymerase (PARP). The activation of PARP leads to an energy consuming inefficient repair cycle with subsequent depletion of NAD+ and ATP pools and necrotic cell death. The present review overviews the pathophysiological role of the peroxynitrite-PARP pathway in cardiac ischemia/reperfusion injury with special reference to the therapeutic potential of PARP inhibitors in the treatment of this disease.
Export Options
About this article
Cite this article as:
Szabo Gabor and Bahrle Susanne, Role of Nitrosative Stress and Poly(ADP-ribose) Polymerase Activation in Myocardial Reperfusion Injury, Current Vascular Pharmacology 2005; 3 (3) . https://dx.doi.org/10.2174/1570161054368599
DOI https://dx.doi.org/10.2174/1570161054368599 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Combination Therapy with Hepatocyte Growth Factor and Oseltamivir Confers Enhanced Protection Against Influenza Viral Pneumonia
Current Molecular Medicine Extracellular Vesicles as Therapeutics for Brain Injury and Disease
Current Pharmaceutical Design Coronary Artery Disease in Patients with Chronic Kidney Disease: A Clinical Update
Current Cardiology Reviews Relevance of Sphingolipids in the Pleiotropic Protective Effects of High-Density Lipoproteins
Current Pharmaceutical Design Diagnostic and Therapeutic Potentials of microRNAs in Heart Failure
Current Topics in Medicinal Chemistry Physiological and Pathological Functions of Acid-Sensing Ion Channels in the Central Nervous System
Current Drug Targets Phosphodiesterase-5 Inhibitors: Future Perspectives
Current Pharmaceutical Design The Role of Microglial Cells on Neuroinflammation: Possible Therapeutic Applications
Recent Patents on Regenerative Medicine Chemical Biology: Past, Present and Future
Current Chemical Biology Editorial (Thematic Issue: Modifying Cardiovascular Risk Factors: Current Opinion and Future Trends)
Current Pharmaceutical Design Corticosteroids for the Inflammatory Response to Cardiopulmonary Bypass: An Update
Current Pharmaceutical Design Mechanisms Underlying Beneficial Health Effects of Tea Catechins to Improve Insulin Resistance and Endothelial Dysfunction
Endocrine, Metabolic & Immune Disorders - Drug Targets Modulation of Inflammation as a Way of Delaying Alzheimer's Disease Progression: The Diet's Role
Current Alzheimer Research Facing Up the ROS Labyrinth - Where To Go?
Current Vascular Pharmacology Efficacy of Pentoxifylline in the Management of Microalbuminuria in Patients with Diabetes
Current Diabetes Reviews Non-Analgesic Effects of Opioids: Neuroprotection in the Retina
Current Pharmaceutical Design Target-based Anti-angiogenic Therapy in Breast Cancer
Current Pharmaceutical Design Effects of Tea Catechins on Inflammation-Related Cardiovascular Diseases
Current Immunology Reviews (Discontinued) Hypoxia-Inducible Factor-1α Contributes to Brain Edema after Stroke by Regulating Aquaporins and Glycerol Distribution in Brain
Current Neurovascular Research Structures Required of Polyphenols for Inhibiting Advanced Glycation end Products Formation
Current Drug Metabolism